A critical review of endpoints for non-cirrhotic NASH therapeutic trials

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502 · see citing works

Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis

Sanyal, A. J., Chalasani, N., Kowdley, K. V., McCullough, A., Diehl, A. M., Bass, N. M., Neuschwander-Tetri, B. A., Lavine, J. E., Tonascia, J., Unalp, A., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907929 · Cited by 3,327 · see citing works

Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease

Angulo, P., Kleiner, D. E., Dam-Larsen, S., Adams, L. A., Bjornsson, E. S., Charatcharoenwitthaya, P., Mills, P. R., Keach, J. C., Lafferty, H. D., Stahler, A., et al. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.043 · Cited by 2,987 · see citing works

Nonalcoholic Fatty Liver, Steatohepatitis, and the Metabolic Syndrome

Marchesini, G., Bugianesi, E., Forlani, G., Cerrelli, F., Lenzi, M., Manini, R., Natale, S., Vanni, E., Villanova, N., Melchionda, N., et al. (2003) · Hepatology · doi:10.1053/jhep.2003.50161 · Cited by 2,676 · see citing works

Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis

Vilar-Gomez, E., Martinez-Perez, Y., Calzadilla-Bertot, L., Torres-Gonzalez, A., Gra-Oramas, B., Gonzalez-Fabian, L., Friedman, S. L., Diago, M., & Romero-Gomez, M. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.04.005 · Cited by 2,492 · see citing works

Homeostasis model assessment closely mirrors the glucose clamp technique in the assessment of insulin sensitivity: Studies in subjects with various degrees of glucose tolerance and insulin sensitivity

Bonora, E., Targher, G., Alberiche, M., Bonadonna, R. C., Saggiani, F., Zenere, M. B., Monauni, T., & Muggeo, M. (2000) · Diabetes Care · doi:10.2337/diacare.23.1.57 · Cited by 2,456 · see citing works

Sampling Variability of Liver Fibrosis in Chronic Hepatitis C

Bédossa, P., Dargère, D., & Paradis, V. (2003) · Hepatology · doi:10.1016/j.hep.2003.09.022 · Cited by 2,370 · see citing works

Long-term follow-up of patients with NAFLD and elevated liver enzymes

Ekstedt, M., Franzén, L. E., Mathiesen, U. L., Thorelius, L., Holmqvist, M., Bodemar, G., & Kechagias, S. (2006) · Hepatology · doi:10.1002/hep.21327 · Cited by 2,302 · see citing works

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): A multicentre, randomised, placebo-controlled trial

Neuschwander-Tetri, B. A., Loomba, R., Sanyal, A. J., Lavine, J. E., Van Natta, M. L., Abdelmalek, M. F., Chalasani, N., Dasarathy, S., Diehl, A. M., Hameed, B., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61933-4 · Cited by 2,237 · see citing works

Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities

Sanyal, A. J., Campbell–Sargent, C., Mirshahi, F., Rizzo, W. B., Contos, M. J., Sterling, R. K., Luketic, V. A., Shiffman, M. L., & Clore, J. N. (2001) · Gastroenterology · doi:10.1053/gast.2001.23256 · Cited by 2,078 · see citing works

Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta‐analysis

Dulai, P. S., Singh, S., Patel, J., Soni, M., Prokop, L. J., Younossi, Z., Sebastiani, G., Ekstedt, M., Hagstrom, H., Nasr, P., et al. (2017) · Hepatology · doi:10.1002/hep.29085 · Cited by 1,965 · see citing works

A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis

Belfort, R., Harrison, S. A., Brown, K., Darland, C., Finch, J., Hardies, J., Balas, B., Gastaldelli, A., Tio, F., Pulcini, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060326 · Cited by 1,827 · see citing works

Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: A 5-year open-label follow-up study

Marcellin, P., Gane, E., Buti, M., Afdhal, N., Sievert, W., Jacobson, I. M., Washington, M. K., Germanidis, G., Flaherty, J. F., Schall, R. A., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61425-1 · Cited by 1,788 · see citing works

Dietary and Genetic Obesity Promote Liver Inflammation and Tumorigenesis by Enhancing IL-6 and TNF Expression

Park, E. J., Lee, J. H., Yu, G.-Y., He, G., Ali, S. R., Holzer, R. G., Österreicher, C. H., Takahashi, H., & Karin, M. (2010) · Cell · doi:10.1016/j.cell.2009.12.052 · Cited by 1,764 · see citing works

Fibrosis Progression in Nonalcoholic Fatty Liver vs Nonalcoholic Steatohepatitis: A Systematic Review and Meta-analysis of Paired-Biopsy Studies

Singh, S., Allen, A. M., Wang, Z., Prokop, L. J., Murad, M. H., & Loomba, R. (2015) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.04.014 · Cited by 1,748 · see citing works

Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population

Szczepaniak, L. S., Nurenberg, P., Leonard, D. S., Browning, J. D., Reingold, J. S., Grundy, S. M., Hobbs, H. H., & Dobbins, R. L. (2004) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00064.2004 · Cited by 1,562 · see citing works

Treatment of NAFLD with diet, physical activity and exercise

Romero-Gómez, M., Zelber-Sagi, S., & Trenell, M. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.05.016 · Cited by 1,347 · see citing works

The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice

Xu, A., Wang, Y., Keshaw, H., Xu, L. Y., Lam, K. S. L., & Cooper, G. J. S. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17797 · Cited by 1,298 · see citing works

The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice

Xu, A., Wang, Y., Keshaw, H., Xu, L. Y., Lam, K. S. L., & Cooper, G. J. S. (2003) · Journal of Clinical Investigation · doi:10.1172/jci200317797 · Cited by 1,298 · see citing works

Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD

Hagström, H., Nasr, P., Ekstedt, M., Hammar, U., Stål, P., Hultcrantz, R., & Kechagias, S. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.07.027 · Cited by 1,067 · see citing works

Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: Implications for prognosis and clinical management

McPherson, S., Hardy, T., Henderson, E., Burt, A. D., Day, C. P., & Anstee, Q. M. (2014) · Journal of Hepatology · doi:10.1016/j.jhep.2014.11.034 · Cited by 1,059 · see citing works

Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening

Ratziu, V., Harrison, S. A., Francque, S., Bedossa, P., Lehert, P., Serfaty, L., Romero-Gomez, M., Boursier, J., Abdelmalek, M., Caldwell, S., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.01.038 · Cited by 1,035 · see citing works

Long-Term Pioglitazone Treatment for Patients With Nonalcoholic Steatohepatitis and Prediabetes or Type 2 Diabetes Mellitus: A Randomized Trial

Cusi, K., Orsak, B., Bril, F., Lomonaco, R., Hecht, J., Ortiz-Lopez, C., Tio, F., Hardies, J., Darland, C., Musi, N., et al. (2016) · Annals of Internal Medicine · doi:10.7326/m15-1774 · Cited by 1,024 · see citing works

Selective versus Total Insulin Resistance: A Pathogenic Paradox

Brown, M. S., & Goldstein, J. L. (2008) · Cell Metabolism · doi:10.1016/j.cmet.2007.12.009 · Cited by 959 · see citing works

Beyond insulin resistance in NASH: TNF-α or adiponectin?

Hui, J. M., Hodge, A., Farrell, G. C., Kench, J. G., Kriketos, A., & George, J. (2004) · Hepatology · doi:10.1002/hep.20280 · Cited by 942 · see citing works

Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease

Mudaliar, S., Henry, R. R., Sanyal, A. J., Morrow, L., Marschall, H., Kipnes, M., Adorini, L., Sciacca, C. I., Clopton, P., Castelloe, E., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2013.05.042 · Cited by 931 · see citing works

Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial

Lindor, K. D., Kowdley, K. V., Heathcote, J. E., Harrison, E. M., Jorgensen, R., Angulo, P., Lymp, J. F., Burgart, L., & Colin, P. (2004) · Hepatology · doi:10.1002/hep.20092 · Cited by 727 · see citing works

Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis

Aithal, G. P., Thomas, J. A., Kaye, P. V., Lawson, A., Ryder, S. D., Spendlove, I., Austin, A. S., Freeman, J. G., Morgan, L., & Webber, J. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.06.047 · Cited by 721 · see citing works

Magnetic Resonance Elastography vs Transient Elastography in Detection of Fibrosis and Noninvasive Measurement of Steatosis in Patients With Biopsy-Proven Nonalcoholic Fatty Liver Disease

Park, C. C., Nguyen, P., Hernandez, C., Bettencourt, R., Ramirez, K., Fortney, L., Hooker, J. C., Sy, E. Z., Savides, M. T., Alquiraish, M. H., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.10.026 · Cited by 715 · see citing works

A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis

Friedman, S. L., Ratziu, V., Harrison, S. A., Abdelmalek, M. F., Aithal, G. P., Caballeria, J., Francque, S., Farrell, G., Kowdley, K. V., Craxi, A., et al. (2018) · Hepatology · doi:10.1002/hep.29477 · Cited by 671 · see citing works

Sampling variability of liver fibrosis in chronic hepatitis C

Bédossa, P. (2003) · Hepatology · doi:10.1053/jhep.2003.09022 · Cited by 667 · see citing works

Pathologic criteria for nonalcoholic steatohepatitis: Interprotocol agreement and ability to predict liver-related mortality

Younossi, Z. M., Stepanova, M., Rafiq, N., Makhlouf, H. R., Younoszai, Z., Agrawal, R., & Goodman, Z. D. (2011) · Hepatology · doi:10.1002/hep.24268 · Cited by 636 · see citing works

Rosiglitazone for Nonalcoholic Steatohepatitis: One-Year Results of the Randomized Placebo-Controlled Fatty Liver Improvement With Rosiglitazone Therapy (FLIRT) Trial

Ratziu, V., Giral, P., Jacqueminet, S., Charlotte, F., Hartemann–Heurtier, A., Serfaty, L., Podevin, P., Lacorte, J., Bernhardt, C., Bruckert, E., et al. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.03.078 · Cited by 625 · see citing works

Increased Lipogenesis, Induced by AKT-mTORC1-RPS6 Signaling, Promotes Development of Human Hepatocellular Carcinoma

Calvisi, D. F., Wang, C., Ho, C., Ladu, S., Lee, S. A., Mattu, S., Destefanis, G., Delogu, S., Zimmermann, A., Ericsson, J., et al. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.12.006 · Cited by 598 · see citing works

Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis

Argo, C. K., Northup, P. G., Al‐Osaimi, A. M. S., & Caldwell, S. H. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.03.019 · Cited by 551 · see citing works

Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials: Hepatology

Noureddin, M., Lam, J., Peterson, M. R., Middleton, M., Hamilton, G., Le, T.-A., Bettencourt, R., Changchien, C., Brenner, D. A., Sirlin, C., et al. (2013) · Hepatology · doi:10.1002/hep.26455 · Cited by 550 · see citing works

The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial

Loomba, R., Lawitz, E., Mantry, P. S., Jayakumar, S., Caldwell, S. H., Arnold, H., Diehl, A. M., Djedjos, C. S., Han, L., Myers, R. P., et al. (2018) · Hepatology · doi:10.1002/hep.29514 · Cited by 549 · see citing works

A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver

Pais, R., Charlotte, F., Fedchuk, L., Bédossa, P., Lebray, P., Poynard, T., & Ratziu, V. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.04.027 · Cited by 520 · see citing works

Transient elastography is unreliable for detection of cirrhosis in patients with acute liver damage

Sagir, A., Erhardt, A., Schmitt, M., & Häussinger, D. (2007) · Hepatology · doi:10.1002/hep.22056 · Cited by 512 · see citing works

Randomized, Placebo-Controlled Trial of Pioglitazone in Nondiabetic Subjects With Nonalcoholic Steatohepatitis

Harnois, D. M. (2009) · Yearbook of Gastroenterology · doi:10.1016/s0739-5930(09)79298-0 · Cited by 505 · see citing works

Multiparametric magnetic resonance for the non-invasive diagnosis of liver disease

Banerjee, R., Pavlides, M., Tunnicliffe, E. M., Piechnik, S. K., Sarania, N., Philips, R., Collier, J. D., Booth, J., Schneider, J. E., Wang, L. M., et al. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.09.002 · Cited by 498 · see citing works

Clinical, Laboratory and Histological Associations in Adults with Nonalcoholic Fatty Liver Disease†

Neuschwander‐Tetri, B. A., Clark, J. M., Bass, N. M., Natta, M. L. V., Ünalp–Arida, A., Tonascia, J. A., Zein, C. O., Brunt, E. M., Kleiner, D. E., McCullough, A. J., et al. (2010) · Hepatology · doi:10.1002/hep.23784 · Cited by 463 · see citing works

Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease

Lomonaco, R., Ortiz‐Lopez, C., Orsak, B., Webb, A., Hardies, J., Darland, C., Finch, J., Gastaldelli, A., Harrison, S. A., Tio, F. O., et al. (2011) · Hepatology · doi:10.1002/hep.25539 · Cited by 461 · see citing works

Liver Fat in the Metabolic Syndrome

Kotronen, A., Westerbacka, J., Bergholm, R., Pietiläinen, K. H., & Yki‐Järvinen, H. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2007-0482 · Cited by 452 · see citing works

Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis: A Meta-analysis

Musso, G., Cassader, M., Paschetta, E., & Gambino, R. (2017) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2016.9607 · Cited by 449 · see citing works

Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro

Galli, A., Crabb, D. W., Ceni, E., Salzano, R., Mello, T., Svegliati–Baroni, G., Ridolfi, F., Trozzi, L., Surrenti, C., & Casini, A. (2002) · Gastroenterology · doi:10.1053/gast.2002.33666 · Cited by 440 · see citing works

A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis

D'Ambrosio, R., Aghemo, A., Rumi, M. G., Ronchi, G., Donato, M. F., Paradis, V., Colombo, M., & Bedossa, P. (2012) · Hepatology · doi:10.1002/hep.25606 · Cited by 409 · see citing works

Ligands of peroxisome proliferator-activated receptor γ modulate profibrogenic and proinflammatory actions in hepatic stellate cells

Marra, F., Efsen, E., Romanelli, R. G., Caligiuri, A., Pastacaldi, S., Batignani, G., Bonacchi, A., Caporale, R., Laffi, G., Pinzani, M., et al. (2000) · Gastroenterology · doi:10.1053/gast.2000.9365 · Cited by 409 · see citing works

Quantification of Hepatic Steatosis with T1-independent, T2*-corrected MR Imaging with Spectral Modeling of Fat: Blinded Comparison with MR Spectroscopy

Meisamy, S., Hines, C. D. G., Hamilton, G., Sirlin, C. B., McKenzie, C. A., Yu, H., Brittain, J. H., & Reeder, S. B. (2011) · Radiology · doi:10.1148/radiol.10100708 · Cited by 383 · see citing works

Long-Term Efficacy of Rosiglitazone in Nonalcoholic Steatohepatitis: Results of the Fatty Liver Improvement by Rosiglitazone Therapy (Flirt 2) Extension Trial

Ratziu, V., Charlotte, F., Bernhardt, C., Giral, P., Halbron, M., Naour, G. L., Hartemann–Heurtier, A., Bruckert, É., & Poynard, T. (2009) · Hepatology · doi:10.1002/hep.23270 · Cited by 363 · see citing works

Challenges and opportunities in drug and biomarker development for nonalcoholic steatohepatitis: Findings and recommendations from an American Association for the Study of Liver Diseases–U.S. Food and Drug Administration Joint Workshop

Sanyal, A. J., Friedman, S. L., McCullough, A. J., & Dimick‐Santos, L. (2014) · Hepatology · doi:10.1002/hep.27678 · Cited by 355 · see citing works

Minireview: IGF, Insulin, and Cancer

Gallagher, E. J., & LeRoith, D. (2011) · Endocrinology · doi:10.1210/en.2011-0231 · Cited by 347 · see citing works

Ezetimibe for the treatment of nonalcoholic steatohepatitis: Assessment by novel magnetic resonance imaging and magnetic resonance elastography in a randomized trial (MOZART trial)

Loomba, R. S., Sirlin, C. B., Ang, B., Bettencourt, R., Jain, R., Salotti, J., Soaft, L., Hooker, J. C., Kono, Y., Bhatt, A., et al. (2014) · Hepatology · doi:10.1002/hep.27647 · Cited by 346 · see citing works

A randomized controlled trial of high-dose ursodesoxycholic acid for nonalcoholic steatohepatitis

Ratziu, V., de Ledinghen, V., Oberti, F., Mathurin, P., Wartelle-Bladou, C., Renou, C., Sogni, P., Maynard, M., Larrey, D., Serfaty, L., et al. (2011) · Journal of Hepatology · doi:10.1016/j.jhep.2010.08.030 · Cited by 338 · see citing works

High‐dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double‐blind, randomized, placebo‐controlled trial†

Leuschner, U. F. H., Lindenthal, B., Herrmann, G., Arnold, J. C., Rössle, M., Cordes, H., Zeuzem, S., Hein, J., & Berg, T. (2010) · Hepatology · doi:10.1002/hep.23727 · Cited by 317 · see citing works

Nonalcoholic Fatty Liver Disease: Diagnostic and Fat-Grading Accuracy of Low-Flip-Angle Multiecho Gradient-Recalled-Echo MR Imaging at 1.5 T

Yokoo, T., Bydder, M., Hamilton, G., Middleton, M. S., Gamst, A. C., Wolfson, T. J., Hassanein, T., Patton, H. M., Lavine, J. E., Schwimmer, J. B., et al. (2009) · Radiology · doi:10.1148/radiol.2511080666 · Cited by 303 · see citing works

Computer-assisted image analysis of liver collagen: Relationship to Ishak scoring and hepatic venous pressure gradient #

Calvaruso, V., Burroughs, A. K., Standish, R. A., Manousou, P., Grillo, F., Leandro, G., Maimone, S., Pleguezuelo, M., Xirouchakis, I., Guerrini, G. P., et al. (2008) · Hepatology · doi:10.1002/hep.22745 · Cited by 288 · see citing works

Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis

Gastaldelli, A., Harrison, S. A., Belfort-Aguilar, R., Hardies, L. J., Balas, B., Schenker, S., & Cusi, K. (2009) · Hepatology · doi:10.1002/hep.23116 · Cited by 285 · cited 2× · see citing works

Agreement Between Magnetic Resonance Imaging Proton Density Fat Fraction Measurements and Pathologist-Assigned Steatosis Grades of Liver Biopsies From Adults With Nonalcoholic Steatohepatitis

Middleton, M. S., Heba, E. R., Hooker, C. A., Bashir, M. R., Fowler, K. J., Sandrasegaran, K., Brunt, E. M., Kleiner, D. E., Doo, E. C., Natta, M. L. V., et al. (2017) · Gastroenterology · doi:10.1053/j.gastro.2017.06.005 · Cited by 278 · see citing works

Limited value of plasma cytokeratin-18 as a biomarker for NASH and fibrosis in patients with non-alcoholic fatty liver disease

Cusi, K. J., Chang, Z., Harrison, S., Lomonaco, R., Bril, F., Orsak, B., Ortiz‐Lopez, C., Hecht, J., Feldstein, A. E., Webb, A., et al. (2013) · Journal of Hepatology · doi:10.1016/j.jhep.2013.07.042 · Cited by 272 · see citing works

Advanced Fibrosis in Nonalcoholic Fatty Liver Disease: Noninvasive Assessment with MR Elastography

Kim, D., Kim, W. R., Talwalkar, J. A., Kim, H. J., & Ehman, R. L. (2013) · Radiology · doi:10.1148/radiol.13121193 · Cited by 229 · see citing works

Dual Peroxisome Proliferator–Activated Receptor α/δ Agonist GFT505 Improves Hepatic and Peripheral Insulin Sensitivity in Abdominally Obese Subjects

Cariou, B., Hanf, R., Lambert-Porcheron, S., Zaïr, Y., Sauvinet, V., Noël, B., Flet, L., Vidal, H., Staels, B., & Laville, M. (2013) · Diabetes Care · doi:10.2337/dc12-2012 · Cited by 216 · see citing works

Multiparametric magnetic resonance imaging predicts clinical outcomes in patients with chronic liver disease

Pavlides, M., Banerjee, R., Sellwood, J., Kelly, C. J., Robson, M. D., Booth, J. C., Collier, J., Neubauer, S., & Barnes, E. (2016) · Journal of Hepatology · doi:10.1016/j.jhep.2015.10.009 · Cited by 212 · see citing works

Magnitude and Kinetics of Decrease in Liver Stiffness After Antiviral Therapy in Patients With Chronic Hepatitis C: A Systematic Review and Meta-analysis

Singh, S., Facciorusso, A., Loomba, R. S., & Falck-Ytter, Y. T. (2017) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2017.04.038 · Cited by 208 · see citing works

Peroxisome proliferator-activated receptor γ transcriptional regulation is involved in platelet-derived growth factor-induced proliferation of human hepatic stellate cells

Galli, A., Crabb, D., Price, D., Ceni, E., Salzano, R., Surrenti, C., & Casini, A. (2000) · Hepatology · doi:10.1002/hep.510310117 · Cited by 197 · see citing works

Multiparametric magnetic resonance imaging for the assessment of non‐alcoholic fatty liver disease severity

Pavlides, M., Banerjee, R., Tunnicliffe, E. M., Kelly, M., Collier, J. D., Wang, L. M., Fleming, K. A., Cobbold, J., Robson, M. D., Neubauer, S., et al. (2016) · Liver International · doi:10.1111/liv.13284 · Cited by 197 · see citing works

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of GS-9450 in Subjects With Nonalcoholic Steatohepatitis

Ratziu, V., Sheikh, M. Y., Sanyal, A. J., Lim, J. K., Conjeevaram, H. S., Chalasani, N., Abdelmalek, M. F., Bakken, A., Renou, C., Palmer, M., et al. (2011) · Hepatology · doi:10.1002/hep.24747 · Cited by 164 · see citing works

Association of noninvasive quantitative decline in liver fat content on MRI with histologic response in nonalcoholic steatohepatitis

Patel, J. R., Bettencourt, R., Cui, J. Y., Salotti, J., Hooker, J. C., Bhatt, A., Hernandez, C., Nguyen, P., Aryafar, H., Valasek, M. A., et al. (2016) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756283x16656735 · Cited by 163 · see citing works

Hepatic hyperplasia in noncirrhotic fatty livers: is obesity-related hepatic steatosis a premalignant condition?

Yang, S. Q., Lin, H. Z., Hwang, J., Chacko, V. P., & Diehl, A. M. (2001) · PubMed · Cited by 151 · see citing works

Progression of fibrosis in advanced chronic hepatitis C

Goodman, Z. D., Becker, R. L., Pockros, P. J., & Afdhal, N. H. (2007) · Hepatology · doi:10.1002/hep.21595 · Cited by 145 · see citing works

Plasma Pro‐C3 (N‐terminal type III collagen propeptide) predicts fibrosis progression in patients with chronic hepatitis C

Nielsen, M. J., Veidal, S. S., Karsdal, M. A., Ørsnes‐Leeming, D. J., Vainer, B., Gardner, S. D., Hamatake, R. K., Goodman, Z. D., Schuppan, D., & Patel, K. (2014) · Liver International · doi:10.1111/liv.12700 · Cited by 144 · see citing works

Liver stiffness diminishes with antiviral response in chronic hepatitis C

Hézode, C., Castéra, L., Roudot‐Thoraval, F., Bouvier‐Alias, M., Rosa, I., Roulot, D. M., Leroy, V., Mallat, A., & Pawlotsky, J. (2011) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2011.04765.x · Cited by 135 · see citing works

Nonalcoholic steatohepatitis versus steatosis: adipose tissue insulin resistance and dysfunctional response to fat ingestion predict liver injury and altered glucose and lipoprotein metabolism

Musso, G., Cassader, M., De Michieli, F., Rosina, F., Orlandi, F., & Gambino, R. (2012) · Hepatology · doi:10.1002/hep.25739 · Cited by 126 · see citing works

Use of HOMA-IR to diagnose non-alcoholic fatty liver disease: a population-based and inter-laboratory study

Isokuortti, E., Zhou, Y., Peltonen, M., Bugianesi, E., Clement, K., Bonnefont-Rousselot, D., Lacorte, J.-M., Gastaldelli, A., Schuppan, D., Schattenberg, J. M., et al. (2017) · Diabetologia · doi:10.1007/s00125-017-4340-1 · Cited by 120 · see citing works

Pioglitazone in the treatment of NASH: the role of adiponectin

Gastaldelli, A., Harrison, S. A., Belfort‐Aguiar, R., Hardies, J., Balas, B., Schenker, S., & Cusi, K. J. (2010) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2010.04405.x · Cited by 113 · see citing works

A Multicenter Randomized Controlled Dose Study of Ursodeoxycholic Acid for Chronic Hepatitis C

Takano, S., Yoshimi, I. T. O., Yokosuka, O., Ohto, M., Uchiumi, K., Hirota, K., & Omata, M. (1994) · Hepatology · doi:10.1002/hep.1840200303 · Cited by 100 · see citing works

Identifying nonalcoholic fatty liver disease patients with active fibrosis by measuring extracellular matrix remodeling rates in tissue and blood

Decaris, M. L., Li, K. W., Emson, C. L., Gatmaitan, M., Liu, S., Wang, Y., Nyangau, E., Colangelo, M., Angel, T. E., Beysen, C., et al. (2016) · Hepatology · doi:10.1002/hep.28860 · Cited by 98 · see citing works

Farglitazar Lacks Antifibrotic Activity in Patients With Chronic Hepatitis C Infection

McHutchison, J. G., Goodman, Z. D., Patel, K., Makhlouf, H. R., Rodriguez‐Torres, M., Shiffman, M. L., Rockey, D. C., Husa, P., Chuang, W., Levine, R. A., et al. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.12.003 · Cited by 91 · see citing works

Quantitative histological-hemodynamic correlations in cirrhosis

Sethasine, S., Jain, D., Groszmann, R. J., & García–Tsao, G. (2011) · Hepatology · doi:10.1002/hep.24805 · Cited by 89 · see citing works

Fibrogenesis assessed by serological type III collagen formation identifies patients with progressive liver fibrosis and responders to a potential antifibrotic therapy

Karsdal, M. A., Henriksen, K., Nielsen, M. J., Byrjalsen, I., Leeming, D. J., Gardner, S. D., Goodman, Z. D., Patel, K., Krag, A. A., Christiansen, C., et al. (2016) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00283.2016 · Cited by 81 · see citing works

Limited therapeutic efficacy of pioglitazone on progression of hepatic fibrosis in rats

Leclercq, I. A. (2006) · Gut · doi:10.1136/gut.2005.079194 · Cited by 67 · see citing works

Digital image analysis of collagen assessment of progression of fibrosis in recurrent HCV after liver transplantation

Manousou, P., Burroughs, A. K., Tsochatzis, E. A., Isgrò, G., Hall, A. R., Green, A., Calvaruso, V., Li, G., Gale, J. D., Burgess, G., et al. (2012) · Journal of Hepatology · doi:10.1016/j.jhep.2012.12.016 · Cited by 58 · see citing works

Lack of Efficacy of an Inhibitor of PDE4 in Phase 1 and 2 Trials of Patients With Nonalcoholic Steatohepatitis

Ratziu, V., Bédossa, P., Francque, S., Larrey, D. G., Aithal, G. P., Serfaty, L., Voiculescu, M., Preoțescu, L., Nevens, F., de Lédinghen, V., et al. (2014) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2014.01.040 · Cited by 54 · see citing works

Low clinical relevance of the nonalcoholic fatty liver disease activity score (NAS) in predicting fibrosis progression

Ekstedt, M., Franzén, L., Mathiesen, U., & Kechagias, S. (2011) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365521.2011.634024 · Cited by 53 · see citing works

Dual Peroxisome Proliferator-Activated Receptor alpha/delta Agonist GFT505 Improves Hepatic and Peripheral Insulin Sensitivity in Abdominally Obese Subjects.

Cariou, B., Hanf, Lambert-Porcheron, S., & Zair (2013) · Diabetes Care · Cited by 49 · see citing works

Cullin7: a new gene involved in liver carcinogenesis related to metabolic syndrome

Paradis, V., Albuquerque, M., Mebarki, M., Hernandez, L., Zalinski, S., Quentin, S., Belghiti, J., Soulier, J., & Bédossa, P. (2012) · Gut · doi:10.1136/gutjnl-2012-302091 · Cited by 47 · see citing works

Treatment of NASH with ursodeoxycholic acid: Pro

Ratziu, V. (2012) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/s2210-7401(12)70020-7 · Cited by 32 · see citing works

Efficacy and safety of simtuzumab for the treatment of nonalcoholic steatohepatitis with bridging fibrosis or cirrhosis: results of two phase 2b, dose-ranging, randomized, placebo-controlled trials

Sanyal, A. J., Abdelmalek, M. F., Diehl, A., Caldwell, S. H., Shiffman, M., Ghalib, R., Lawitz, E., Rockey, D. C., Schall, R. A., Jia, C., et al. (2017) · Journal of Hepatology · doi:10.1016/s0168-8278(17)30370-7 · Cited by 26 · see citing works

A comparison of the fibrotic potential of nonalcoholic fatty liver disease and chronic hepatitis C

Charlotte, F., Naour, G. L., Bernhardt, C., Poynard, T., & Ratziu, V. (2010) · Human Pathology · doi:10.1016/j.humpath.2009.10.025 · Cited by 18 · see citing works

NGM282, a novel variant of FGF19, significantly reduces hepatic steatosis and key biomarkers of NASH: results of a Phase 2, multicenter, randomized, double-blinded, placebo controlled trial in biopsy-confirmed NASH patients

Harrison, S. A., Abdelmalek, M. F., Trotter, J. F., Paredes, A. H., Arnold, H. L., Kugelmas, M., Bashir, M. R., Ling, L., Rossi, S. J., DePaoli, A. M., et al. (2017) · Journal of Hepatology · doi:10.1016/s0168-8278(17)30448-8 · Cited by 16 · see citing works

Adiponectin suppresses endoplasmic reticulum stress in nonalcoholic steatohepatitis

Ueno, T., Nakamura, A., Nakayama, H., Otabe, S., Yuan, X., Fukutani, T., Iwamoto, H., Nakamura, T., Koga, H., Torimura, T., et al. (2011) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2011.348 · Cited by 14 · see citing works

Changes in fibrosis, but not the NAFLD Activity Score (NAS), are associated with disease progression in patients with nonalcoholic steatohepatitis (NASH) and advanced fibrosis

Sanyal, A. J., Harrison, S. A., Ratziu, V., Abdelmalek, M. F., Diehl, A. M., Caldwell, S. H., Shiffman, M. L., Aguilar, R., Jia, C., Mccolgan, B., et al. (2017) · Journal of Hepatology · doi:10.1016/s0168-8278(17)30267-2 · Cited by 10 · see citing works

Improvement in NASH histological activity highly correlates with fibrosis regression

Ratziu, V., Francque, S., Harrison, S., Anstee, Q. M., Bedossa, P., Brozek, J., Hum, D. W., Megnien, S. J., Roudot, A., Hanf, R., et al. (2016) · Newcastle University ePrints (Newcastle Univesity) · doi:10.25405/ncl.34302153 · Cited by 10 · see citing works

EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis – 2021 update

Berzigotti, A., Tsochatzis, E., Boursier, J., Castera, L., Cazzagon, N., Friedrich-Rust, M., Petta, S., & Thiele, M. (2021) · Journal of Hepatology · doi:10.1016/j.jhep.2021.05.025 · Cited by 1,925 · see citing works

Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies

Stefan, N., Häring, H., & Cusi, K. J. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30154-2 · Cited by 848 · see citing works

Metabolomics and lipidomics in NAFLD: biomarkers and non-invasive diagnostic tests

Masoodi, M., Gastaldelli, A., Hyötyläinen, T., Arretxe, E., Alonso, C., Gaggini, M., Brosnan, J., Anstee, Q. M., Millet, O., Ortiz, P., et al. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00502-9 · Cited by 451 · see citing works

Mouse Models of Nonalcoholic Steatohepatitis: Toward Optimization of Their Relevance to Human Nonalcoholic Steatohepatitis

Farrell, G., Schattenberg, J. M., Leclercq, I., Yeh, M. M., Goldin, R., Teoh, N., & Schuppan, D. (2019) · Hepatology · doi:10.1002/hep.30333 · Cited by 313 · see citing works

Report on the AASLD/EASL joint workshop on clinical trial endpoints in NAFLD

Rinella, M. E., Tacke, F., Sanyal, A. J., & Anstee, Q. M. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.04.019 · Cited by 209 · see citing works

Management of non-alcoholic fatty liver disease

Petroni, M. L., Brodosi, L., Bugianesi, E., & Marchesini, G. (2021) · BMJ · doi:10.1136/bmj.m4747 · Cited by 181 · see citing works

Found in translation—Fibrosis in metabolic dysfunction–associated steatohepatitis (MASH)

Wang, S., & Friedman, S. L. (2023) · Science Translational Medicine · doi:10.1126/scitranslmed.adi0759 · Cited by 158 · see citing works

Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials

Mantovani, A., Byrne, C. D., Scorletti, E., Mantzoros, C. S., & Targher, G. (2020) · Diabetes & Metabolism · doi:10.1016/j.diabet.2019.12.007 · Cited by 138 · see citing works

Report on the AASLD/EASL Joint Workshop on Clinical Trial Endpoints in NAFLD

Rinella, M. E., Tacke, F., Sanyal, A. J., Anstee, Q. M., & Workshop, O. B. O. T. P. O. T. A. (2019) · Hepatology · doi:10.1002/hep.30782 · Cited by 120 · see citing works

EDP-305 in patients with NASH: a phase II double-blind placebo-controlled dose-ranging study

Ratziu, V., Rinella, M. E., Neuschwander-Tetri, B. A., Lawitz, E., Denham, D., Kayali, Z., Sheikh, A., Kowdley, K. V., Desta, T., Elkhashab, M., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2021.10.018 · Cited by 123 · see citing works

Bile acid modulators for the treatment of nonalcoholic steatohepatitis (NASH)

Fiorucci, S., Biagioli, M., Sepe, V., Zampella, A., & Distrutti, E. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1763302 · Cited by 99 · see citing works

Persistence of severe liver fibrosis despite substantial weight loss with bariatric surgery

Pais, R., Aron‐Wisnewsky, J., Bedossa, P., Ponnaiah, M., Oppert, J., Siksik, J., Genser, L., Charlotte, F., Thabut, D., Clement, K., et al. (2022) · Hepatology · doi:10.1002/hep.32358 · Cited by 95 · see citing works

Evaluation of PXL065–deuterium-stabilized (R)-pioglitazone in patients with NASH: a phase II randomized placebo-controlled trial (DESTINY-1)

Harrison, S. A., Thang, C., Bolze, S., Dewitt, S., Hallakou-Bozec, S., Dubourg, J., Bedossa, P., Cusi, K., Ratziu, V., Grouin, J.-M., et al. (2023) · Journal of Hepatology · doi:10.1016/j.jhep.2023.02.004 · Cited by 96 · see citing works

Improvement of non‐invasive markers of NAFLD from an individualised, web‐based exercise program

Huber, Y., Pfirrmann, D., Gebhardt, I., Labenz, C., Gehrke, N., Straub, B. K., Ruckes, C., Bantel, H., Belda, E., Clément, K., et al. (2019) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15427 · Cited by 94 · see citing works

Molecular characterization and cell type composition deconvolution of fibrosis in NAFLD

Pantano, L., Agyapong, G., Shen, Y., Zhuo, Z., Fernández-Albert, F., Rust, W., Knebel, D., Hill, J., Boustany, C., Doerner, J. F., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-96966-5 · Cited by 94 · see citing works

Recent research trends and updates on nonalcoholic fatty liver disease

Yoo, J., Kim, W. K., Kim, M. Y., Jun, D. W., Kim, S. G., Yeon, J.-E., Lee, J. W., Cho, Y. K., Park, S. H., & Sohn, J. H. (2018) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2018.0037 · Cited by 92 · see citing works

Hepatoprotective effects of semaglutide, lanifibranor and dietary intervention in the GAN diet‐induced obese and biopsy‐confirmed mouse model of NASH

Møllerhøj, M. B., Veidal, S. S., Tølbøl, K. S., Oró, D., Overgaard, A., Salinas, C. G., Madsen, M. R., Pfisterer, L., Vyberg, M., Simon, E., et al. (2022) · Clinical and Translational Science · doi:10.1111/cts.13235 · Cited by 83 · see citing works

Recent advances in nonalcoholic fatty liver disease metabolomics

Kim, H. Y. (2021) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2021.0127 · Cited by 80 · see citing works

The nonalcoholic steatohepatitis (NASH) drug development graveyard: established hurdles and planning for future success

Drenth, J. P. H., & Schattenberg, J. M. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1839888 · Cited by 72 · see citing works

Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) for the management of nonalcoholic fatty liver disease (NAFLD): A systematic review

Lv, X., Dong, Y., Hu, L., Lu, F., Zhou, C., & Qin, S. (2020) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.163 · Cited by 64 · see citing works

Automated computerized image analysis for the user-independent evaluation of disease severity in preclinical models of NAFLD/NASH

Rudder, M. D., Bouzin, C., Nachit, M., Louvegny, H., Velde, G. V., Julé, Y., & Leclercq, I. (2019) · Laboratory Investigation · doi:10.1038/s41374-019-0315-9 · Cited by 46 · see citing works

Animal Models of Fibrosis in Nonalcoholic Steatohepatitis: Do They Reflect Human Disease?

Ipsen, D. H., Lykkesfeldt, J., & Tveden-Nyborg, P. (2020) · Advances in Nutrition · doi:10.1093/advances/nmaa081 · Cited by 51 · see citing works

Concurrent nonalcoholic fatty liver disease and type 2 diabetes: diagnostic and therapeutic considerations

Arrese, M. A., Francisco Barrera, M., Triantafilo, N., & Arab, J. P. (2019) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2019.1649981 · Cited by 55 · see citing works

Updates on novel pharmacotherapeutics for the treatment of nonalcoholic steatohepatitis

Yang, Y., Xie, L. H., Zhang, N., Zhou, D., Liu, T., & Wu, J. H. (2022) · Acta Pharmacologica Sinica · doi:10.1038/s41401-022-00860-3 · Cited by 53 · see citing works

AI-based automation of enrollment criteria and endpoint assessment in clinical trials in liver diseases

Iyer, J. S., Juyal, D., Le, Q., Shanis, Z., Pokkalla, H., Pouryahya, M., Pedawi, A., Stanford-Moore, S. A., Biddle-Snead, C., Carrasco-Zevallos, O., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03172-7 · Cited by 54 · see citing works

Efficacy of GLP-1-based Therapies on Metabolic Dysfunction-associated Steatotic Liver Disease and Metabolic Dysfunction-associated Steatohepatitis: A Systematic Review and Meta-analysis

Wang, Y., Zhou, Y., Wang, Z., Ni, Y., Prud’homme, G. J., & WANG, Q. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf336 · Cited by 51 · see citing works

Regression of liver fibrosis: evidence and challenges

Sun, Y., Chen, S., & You, H. (2020) · Chinese Medical Journal · doi:10.1097/cm9.0000000000000835 · Cited by 46 · see citing works

Digital pathology: accurate technique for quantitative assessment of histological features in metabolic‐associated fatty liver disease

Aguado, D. M., Rodríguez, A., Mestre‐Alagarda, C., Bauza, M. E., Valero‐Pérez, E., Alfaro‐Cervelló, C., Benlloch, S., Pérez‐Rojas, J., Ferrández, A., Monraval, P. A., et al. (2020) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16100 · Cited by 39 · see citing works

Canagliflozin and Metabolic Associated Fatty Liver Disease in Patients With Diabetes Mellitus: New Insights From CANVAS

Borisov, A. N., Kutz, A., Christ, E., Heim, M. H., & Ebrahimi, F. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad249 · Cited by 37 · see citing works

Cardiovascular Risk Categories in Patients With Nonalcoholic Fatty Liver Disease and the Role of Low‐Density Lipoprotein Cholesterol

Labenz, C., Prochaska, J. H., Huber, Y., Nagel, M., Straub, B. K., Wild, P. S., Galle, P. R., & Schattenberg, J. M. (2019) · Hepatology Communications · doi:10.1002/hep4.1428 · Cited by 35 · see citing works

Meta‐analysis: analysis of mechanistic pathways in the treatment of non‐alcoholic steatohepatitis. Evidence from a Bayesian network meta‐analysis

Muthiah, M. D., Ng, C. H., Xiao, J., Chin, Y. H., Lim, G., Lim, W. H., Tay, P. W. L., Tan, D. J. H., Yong, J. N., Pan, X., et al. (2022) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.16808 · Cited by 32 · see citing works

Beinaglutide shows significantly beneficial effects in diabetes/obesity-induced nonalcoholic steatohepatitis in ob/ob mouse model

Fang, X., Du, Z., Duan, C., Zhan, S., Wang, T., Zhu, M., Shi, J., Meng, J., Zhang, X., Yang, M., et al. (2021) · Life Sciences · doi:10.1016/j.lfs.2020.118966 · Cited by 29 · see citing works

Metabolic dysfunction−associated liver disease and diabetes: Matrix remodeling, fibrosis, and therapeutic implications

Fan, W., Bradford, T. M., & Török, N. J. (2024) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.15184 · Cited by 25 · see citing works

Effect of pharmacological interventions and placebo on liver Histology in nonalcoholic steatohepatitis: A network meta-analysis

Pennisi, G., Celsa, C., Enea, M., Vaccaro, M., Marco, V. D., Ciccioli, C., Infantino, G., Mantia, C. L., Parisi, S., Vernuccio, F., et al. (2022) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2022.07.001 · Cited by 23 · see citing works

Akkermansia muciniphila in the small intestine improves liver fibrosis in a murine liver cirrhosis model

Oguri, N., Miyoshi, J., Nishinarita, Y., Wada, H., Nemoto, N., Hibi, N., Kawamura, N., Miyoshi, S., Lee, S. T. M., Matsuura, M., et al. (2024) · npj Biofilms and Microbiomes · doi:10.1038/s41522-024-00564-y · Cited by 22 · see citing works

Characterization of six clinical drugs and dietary intervention in the nonobese CDAA-HFD mouse model of MASH and progressive fibrosis

Nielsen, M. H., Nøhr-Meldgaard, J., Møllerhøj, M. B., Oró, D., Pors, S. E., Andersen, M. W., Kamzolas, I., Petsalaki, E., Vacca, M., Harder, L. M., et al. (2024) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00110.2024 · Cited by 20 · see citing works

Evaluation of the severity of nonalcoholic fatty liver disease through analysis of serum exosomal miRNA expression

Gim, J., Bang, S. M., Lee, Y., Lee, Y., Yim, S. Y., Jung, Y. K., Kim, H., Kim, B., Kim, J. H., Seo, Y. S., et al. (2021) · PLoS ONE · doi:10.1371/journal.pone.0255822 · Cited by 19 · see citing works

Current status and challenges in the drug treatment for fibrotic nonalcoholic steatohepatitis

Shi, Y., & Fan, J. (2021) · Acta Pharmacologica Sinica · doi:10.1038/s41401-021-00822-1 · Cited by 19 · see citing works

Liver-specific knockout of B cell lymphoma 6 suppresses progression of non-alcoholic steatohepatitis in mice

Chikada, H., Ida, K., Nishikawa, Y., Inagaki, Y., & Kamiya, A. (2020) · Scientific Reports · doi:10.1038/s41598-020-66539-z · Cited by 17 · see citing works

NAFLD: The evolving landscape

George, J., Anstee, Q. M., Ratziu, V., & Sanyal, A. J. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.11.016 · Cited by 17 · see citing works

Design, Synthesis, and Pharmacological Evaluation of Dual FXR-LIFR Modulators for the Treatment of Liver Fibrosis.

Rapacciuolo, P., Finamore, C., Giorgio, C. D., Fiorillo, B., Massa, C., Urbani, G., Marchianò, S., Bordoni, M., Cassiano, C., Morretta, E., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01651 · Cited by 13 · see citing works

End-points for drug treatment in NASH

Adams, L. A. (2019) · Hepatology International · doi:10.1007/s12072-019-09935-6 · Cited by 16 · see citing works

Liver function tests and metabolic-associated fatty liver disease: Changes in upper normal limits, does it really matter?

Forlano, R., Mullish, B. H., Dhar, A., Goldin, R. D., Thursz, M. R., & Manousou, P. (2021) · World Journal of Hepatology · doi:10.4254/wjh.v13.i12.2104 · Cited by 14 · see citing works

Pharmacotherapeutic Impact on Nonalcoholic Steatohepatitis Histology: A Systematic Review and Network Meta-analysis

Kovalic, A. J. (2022) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2022.01.011 · Cited by 14 · see citing works

AI-based histologic scoring enables automated and reproducible assessment of enrollment criteria and endpoints in NASH clinical trialsPreprint

Iyer, J. S., Pokkalla, H., Biddle-Snead, C., Carrasco‐Zevallos, O. M., Lin, M., Shanis, Z., Le, Q., Juyal, D., Pouryahya, M., Pedawi, A., et al. (2023) · medRxiv · doi:10.1101/2023.04.20.23288534 · Cited by 13 · see citing works

Pharmacotherapeutic efficacy on noninvasive fibrosis progression in nonalcoholic fatty liver disease: a systematic review and network meta-analysis

Kovalic, A. J., Gozar, M., Da, B. L., Bernstein, D., & Satapathy, S. K. (2022) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000002463 · Cited by 13 · see citing works

Future Treatment Options and Regimens for Nonalcoholic Fatty Liver Disease

Francque, S., & Ratziu, V. (2023) · Clinics in Liver Disease · doi:10.1016/j.cld.2023.01.010 · Cited by 12 · see citing works

The future R&D landscape in non-alcoholic steatohepatitis (NASH)

Black, D., Brockbank, S., Cruwys, S., Goldenstein, K., Hein, P., & Humphries, B. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.09.020 · Cited by 9 · see citing works

Learnings From the Graveyard of Phase 2 and 3 Nonalcoholic Steatohepatitis Trials

Francque, S. M., Noureddin, M., & Krag, A. (2024) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2023.07.013 · Cited by 9 · see citing works

Peculiarities of Cirrhosis due to Nonalcoholic Steatohepatitis (NASH)

El‐Sherif, O., & Armstrong, M. J. (2019) · Seminars in Liver Disease · doi:10.1055/s-0039-1697616 · Cited by 8 · see citing works

Overexpression of wild-type HRAS drives non-alcoholic steatohepatitis to hepatocellular carcinoma in mice

Ling, C., 西北大学生命科学学院陕西省生物技术省重点实验室, 陕. 西. 7., Liu, S., Wang, Y., Huo, G., Yang, Y., Xu, N., Wang, H., Wu, Y., Miao, Y., et al. (2024) · 动物学研究 · doi:10.24272/j.issn.2095-8137.2024.002 · Cited by 8 · see citing works

Designing an exploratory phase 2b platform trial in NASH with correlated, co-primary binary endpoints

Meyer, E. L., Mesenbrink, P. G., Prospero, N. A. D., Pericàs, J. M., Glimm, E., Ratziu, V., Sena, E., König, F., & on behalf of the EU-PEARL NASH Investigators (2023) · PLoS ONE · doi:10.1371/journal.pone.0281674 · Cited by 7 · see citing works

Fructose intake is not associated to the risk of hepatic fibrosis in patients with Non-Alcoholic Fatty Liver Disease (NAFLD)

Azevedo, V. Z., & Dall’Alba, V. (2021) · Clinical Nutrition · doi:10.1016/j.clnu.2021.01.022 · Cited by 7 · see citing works

Evaluation of the severity of nonalcoholic fatty liver disease by the analysis of serum exosomal miRNA expressionPreprint

Gim, J., Bang, S. M., Lee, Y., Lee, Y., Yim, S. Y., Jung, Y. K., Kim, J. H., Seo, Y. S., Yim, H. J., Yeon, J. E., et al. (2021) · Research Square · doi:10.21203/rs.3.rs-134447/v1 · Cited by 6 · see citing works

Cytokines, paraoxonase‑1, periostin and non‑invasive liver fibrosis scores in patients with non‑alcoholic fatty liver disease and persistently elevated aminotransferases: A pilot study

Milaciu, M. V., Ciumărnean, L., Matei, D. M., Vesa, Ș. C., Sabin, O., Bocșan, I. C., Pop, R. M., Negrean, V., Buzoianu, A. D., & Acalovschi, M. (2021) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2021.9965 · Cited by 5 · see citing works

A Class Effect Network Meta-analysis of Lipid Modulation in Non-alcoholic Steatohepatitis for Dyslipidemia

Xiao, J., Ng, C. H., Chin, Y. H., Tan, D. J. H., Lim, W. H., Lim, G., Quek, J., Tang, A. S. P., Chan, K. E., Soong, R. Y., et al. (2022) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2022.00095 · Cited by 5 · see citing works

Reading the stars for hepatic fibrosis or how to predict the severity of liver disease in patients with NASH

Schattenberg, J. M. (2019) · Liver International · doi:10.1111/liv.13999 · Cited by 5 · see citing works

Fetal pulmonary artery Doppler parameters in pregnancies complicated with intrahepatic cholestasis of pregnancy: a prospective case-control study

Yakıştıran, B., Tanaçan, A., Altınboğa, O., Elbayiyev, S., Canpolat, F. E., & Yücel, A. (2022) · Journal of the Turkish-German Gynecological Association · doi:10.4274/jtgga.galenos.2021.2021-9-21 · Cited by 4 · see citing works

Neues zur nichtalkoholischen Steatohepatitis

Stefan, N. (2019) · Der Internist · doi:10.1007/s00108-018-0550-y · Cited by 4 · see citing works

Efficacy and Safety of Ezetimibe for Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis

Boskabadi, A. R., Khodabandelu, S., Rahimi, Y., Motamedi, A., Asili, P., Ghasempour, A., Keshavarzian, A., Noori, S., & Rahmanian, M. (2025) · Current Clinical Pharmacology · doi:10.2174/0127724328371387250606060831 · Cited by 3 · see citing works

Evaluation of emerging NASH therapies: the impact of treatment efficacy profiles on long-term health outcomes

Herring, W. L., Gould, I. G., Wittrup-Jensen, V., Ertle, J., Kuti, E. L., & Wolowacz, S. E. (2022) · Journal of Comparative Effectiveness Research · doi:10.2217/cer-2021-0194 · Cited by 2 · see citing works

Research and clinical trial design in patients with metabolic dysfunction and alcohol-associated steatotic liver disease (MetALD): a narrative review

Acuña, P., ALBHAISI, O. A., Idalsoaga, F. J., Alkhouri, N., Noureddin, M., Díaz, L. A., & Arab, J. P. (2025) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2025.61 · Cited by 1 · see citing works

The immunometabolic mechanisms and therapeutic targets of metabolic dysfunction-associated steatohepatitis

Yu, J., & Peng, Y. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1801906 · Cited by 1 · see citing works

The use of FGF21 analogues in MASH and MASH cirrhosis – metabolic master regulators or liver-specific mechanisms?

Holleboom, A. G., & Schattenberg, J. M. (2026) · JHEP Reports · doi:10.1016/j.jhepr.2026.101957 · Cited by 1 · see citing works

Histological Endpoints for Nonalcoholic Steatohepatitis Trials: Lights and Shadows

Rowe, I. A. C. (2020) · Seminars in Liver Disease · doi:10.1055/s-0040-1709491 · Cited by 1 · see citing works

Second harmonic generation digital pathology with artificial intelligence: breakthroughs in studying fibrosis dynamics and treatment response

Naoumov, N. V., & Chng, E. (2024) · Future Medicine AI · doi:10.2217/001c.121609 · Cited by 1 · see citing works

Endpunkte klinischer Studien

Tacke, F. (2022) · Springer eBooks · doi:10.1007/978-3-662-62484-5_36 · Cited by 1 · see citing works

Imaging endpoints for non-alcoholic steatohepatitis (NASH) therapeutic trials: A growing role for multiparametric MRI?

Banerjee, R., Kelly, M., Wilman, H., Wright, T. L., & Neubauer, S. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.04.022 · Cited by 1 · see citing works

Associations between Abnormal Iron Metabolism and Elevated Alanine Aminotransferase in AdultsPreprint

Su, X., Zhang, D., Chen, Z., Han, X., Xia, P., Yin, M., & Zhu, H. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4167832

The Treatment Progression of Obeticholic Acid in Non-Alcoholic Fatty Liver Disease

董, 方. (2022) · Advances in Clinical Medicine · doi:10.12677/acm.2022.12121643

Efsubaglutide Alfa attenuates metabolic dysfunction‐associated steatohepatitis in mice with improvements in second harmonic generation‐derived fibrosis features

Wang, Y., WANG, Z., Yan, G., Peng, C., Chen, L., Yan, R., & WANG, Q. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70495 · Cited by 1 · see citing works

Mise au point d’un nouvel outil diagnostique de l’obésité sarcopénique : relations avec la dysfonction du tissu adipeux, l’insulinorésistance et la sévérité de l’atteinte hépatique

Azevedo, V. Z. (2024) · theses.fr (ABES) · doi:10.70675/6f7a5047ze3eaz482fzaae4zb7f1dc7abc0a

BindingDB Entry 50022654: Design, Synthesis, and Pharmacological Evaluation of Dual FXR-LIFR Modulators for the Treatment of Liver Fibrosis.

BindingDB (2026) · UC San Diego · doi:10.7270/q2kk9hmf

End-points for drug treatment in NASH

Adams, L. A. (2019) · Hepatology International · doi:10.1007/s12072-019-09935-6 · Cited by 16 · see citing works

Defining Improvement in Nonalcoholic Steatohepatitis for Treatment Trial Endpoints: Recommendations From the Liver Forum

Cheung, A. C., Neuschwander‐Tetri, B. A., Kleiner, D. E., Schabel, E., Rinella, M. E., Harrison, S. A., Ratziu, V., Sanyal, A. J., Loomba, R. S., Megnien, S. J., et al. (2019) · Hepatology · doi:10.1002/hep.30672 · Cited by 77 · see citing works

Imaging endpoints for non-alcoholic steatohepatitis (NASH) therapeutic trials: A growing role for multiparametric MRI?

Banerjee, R., Kelly, M., Wilman, H., Wright, T. L., & Neubauer, S. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2018.04.022 · Cited by 1 · see citing works

Surrogate endpoints for clinical trials in non-alcoholic steatohepatitis

Tsochatzis, E. A., Buzzetti, E., & Pinzani, M. (2017) · ˜The œLancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(17)30184-x · Cited by 2 · see citing works

Histological Endpoints for Nonalcoholic Steatohepatitis Trials: Lights and Shadows

Rowe, I. A. C. (2020) · Seminars in Liver Disease · doi:10.1055/s-0040-1709491 · Cited by 1 · see citing works